Endocrinologist Resume Example

Highly-motivated, team-oriented and compassionate Board Certified Endocrinologist with 30 years of clinical experience.

Union College- Magna Cum Laude
Albany Medical College- Alpha Omega Alpha
Albany Medical College- Clinical Golden Apple
American Diabetes Association-2006
Juvenile Diabetes Association- 2013

Internal Medicine - 1983
Endocrinology and Metabolism - 1985

Member- American Diabetes Association
Fellow American Association of Clinical Endocrinology
Member- Alpha Omega Alpha

Principle Investigator:  Medtronic/20G Sure T INfusions Set-User Evaluation April 2009-June 2009

Principle Investigator:  Study to evaluate the efficacy and long-term safety of vildagliptin modified release(MR) as monotherapy in patients with T2DM.  January- 2009

Principle Ivestigator:  The Seven Center Study, Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects with T1DM:  A Multicenter, Randomized Controlled Trial May 2005-June 2006

Principle Investigator:  Liraglutide effect and action in Diabetes (LEAD 4):  Effect of glycemic control of Liraglutide in combination with rosiglitazone plus metformin vs rosiglitazone plus metformin in type 2 diabetes (A fifty two week with fifty two week open label extension) double-blind, multicenter, randomized, parallel study to investigate safety and efficacy) June 2006- January 2007

Principle Investigator:  User Evaluation of the Guardian Real Time ContinuousGlucose Monitoring System.  Medtronic Minimed ProtocolP27/GRTIII September 2006-March 2007

Principle Investigator Healthcare Provider's User Evaluation of the Continuous Glucose Monitoring System iPro:  An Assessment of the Healthcare Provider's Burden and Ease of Use,  Medtronic Minimed Protocol P32/CGMSiPro/A.  July 2007-October 2007

Principle Investigator :  HA prospective, Open-Label, Observational Study Evaluating Symlin (pramlintide acetate) Injection Use in Insulin-using Patients with T1DM and T2DM following Symlin Introduction into the Marketplace.  Protocol 137-161 July 2007-September 2007.

Principle Investigator:  A randomized, parallel Study to Compare Performance of the Human Serum Albumin Sensor to the Bovine Serum Albumin Sensor Protocol.  Medtronic Minimed Protocol P30/Gso41/A

Sub Investigator:  A Multicenter, Randomized, Double blind Placebo controlled, Parallel group study to evaluate the effects of aliskerin on proteinuria when added to standardized losartan therapy and optimal antihypertensive therapy in patients with hypertension and T2DM.  2004-2007

Sensor Augmented Pump Therapy:  Results of the First Treat to Target Study. Irl B Hirsch, Bruce W Bode, Jill M Abelseth , Jerome Se Fischer, Francine R Kaufman, John Mastrototaro, Howard A Wolpert, Bruce A Buckingham.

Irl B Hirsch, MD, Jill M Abelseth MD., Bruce W Bode MD, Jerome S Fischer, MD, Francine R Kaufman, MD John Mastrotataro, PhD, Christopher G Parkin, MS, Howard A Wolpert, MD and Bruce A Buckingham MD.  Sensor -Augmented Insulin Pump Therapy:  Results of the First Randomized Treat-to-Target Study:  Diabetes Technology and Therapeutics, 2008 Volume 10, Number 5  377-383

Consensus Statement by the American Association of Clinical Endocrinologist/American College of Endocrinology Insulin Pump Management Task Force.  George Grunberger, MD, FACP FACE (chair), Jill M Abelseth, MD FACE,  Timothy S. Bailey MD, FACP FACE,  ECNU, Bruce W Bode MD,  FACE, Yehuda Handelsman, MD, FACP FACE, FNLA,  Richard Hellman MD, FACP, FACE, Lois Jovanovic MD,, MACE,  Wndy S Lande, MD,  Philip Raskin MD, FACE, William V Tamborlane MD,  Caitlin Rothermel MA(medical writer)   Endocrine Practice Vol 20 No 5 May 2014. Pg 463

Medtronic Advisory Board

CEC- Medtronic

DSMB- Medtronic